Arcturus Therapeutics Logo
US03969T1097
A2PMAS
ARCT

Arcturus Therapeutics

Previsioni

Il prezzo obiettivo medio degli analisti è 27,80 € (+309,43%). La mediana è 27,80 € (+309,43%).

Acquista
  12
Mantieni
  5
Vendi
  4

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon

    Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Altro su de.investing.com


  • Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts

    At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Altro su de.investing.com


  • Arcturus Therapeutics jumps after management signal and conference announcements

    Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Altro su de.investing.com


  • Arcturus highlights strong liquidity and upcoming clinical catalysts

    Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Altro su de.investing.com


  • Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop

    Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Altro su de.investing.com

Nel 2012, Arcturus Therapeutics ha già distribuito 2,66 € di dividendi. L'ultimo pagamento è avvenuto a dicembre 2012.

Dati finanziari

Nell'ultimo trimestre, Arcturus Therapeutics ha registrato ricavi pari a 16,15 Mln € e un utile netto di -6,55 Mln €

(EUR) settembre 2026
YoY
Ricavi 16,15 Mln 10,53%
Utile lordo 16,15 Mln 37,28%
Utile netto -6,55 Mln 42,88%
EBITDA -6,55 Mln 39,45%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
211,19 Mln €
Numero di azioni
28,82 Mln
Massimo/minimo a 52 settimane
16,37 € - 5,01 €
Dividendi No
Beta
2,61
Rapporto P/E
-2,59
Rapporto PEG
0,10
Rapporto P/B
1,36
Rapporto P/S
9,29

Profilo aziendale

Arcturus Therapeutics Holdings Inc., un'azienda di farmaci a base di RNA, si concentra nello sviluppo di vaccini per malattie infettive, nonché di terapie per malattie rare del fegato e dell'apparato respiratorio negli Stati Uniti. I programmi di sviluppo dell'azienda comprendono il programma LUNAR-OTC per il deficit di ornitina transcarbamilasi (OTC); e il programma LUNAR-CF per la malattia polmonare da fibrosi cistica causata da mutazioni nel gene del regolatore di conduttanza transmembrana della fibrosi cistica (CFTR), oltre ai programmi vaccinali LUNAR-COV19 e LUNAR-FLU. Ha partnership di collaborazione con Vinbiocare Biotechnology Joint Stock Company per la produzione di vaccini contro la COVID-19; Janssen Pharmaceuticals, Inc. per lo sviluppo di candidati terapeutici a base di acidi nucleici per il trattamento del virus dell'epatite B; Ultragenyx Pharmaceutical, Inc. per lo sviluppo di candidati terapeutici a mRNA per bersagli di malattie rare; CureVac AG per lo sviluppo di candidati terapeutici e vaccinali a mRNA per varie indicazioni; Singapore Economic Development Board e Duke-NUS Medical School per lo sviluppo del vaccino LUNAR-COV19; e Millennium Pharmaceuticals, Inc. per la scoperta di farmaci a base di siRNA per il trattamento della steatoepatite non alcolica. La società è stata fondata nel 2013 e ha sede a San Diego, California.

Nome
Arcturus Therapeutics
CEO
Joseph E. Payne
Sede centrale San Diego, ca
Stati Uniti
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
22/05/2013
Dipendenti 109

Simboli di borsa

Borsa Simbolo
NASDAQ
ARCT
🍪

Parqet  usa i cookie. Scopri di più